S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Immune Therapeutics Stock Forecast, Price & News

-0.17 (-8.90%)
(As of 01/14/2022 03:57 PM ET)
Today's Range
50-Day Range
52-Week Range
7,600 shs
Average Volume
1,757 shs
Market Capitalization
$838.68 thousand
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IMUN News and Ratings via Email

Sign-up to receive the latest news and ratings for Immune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Immune Therapeutics logo

About Immune Therapeutics

Immune Therapeutics, Inc. is a biopharmaceutical company focused on the licensing and development of prescription medications for humans in Africa, Central and South America, the Caribbean and China. The company was founded by Noreen Griffin on December 2, 1993 and is headquartered in Winter Park, FL.


The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
December 25, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Net Income
$1.59 million
Pretax Margin




Free Float
Market Cap
$838.68 thousand
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.15 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Immune Therapeutics (OTCMKTS:IMUN) Frequently Asked Questions

How were Immune Therapeutics' earnings last quarter?

Immune Therapeutics, Inc. (OTCMKTS:IMUN) announced its quarterly earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter.
View Immune Therapeutics' earnings history

Who are Immune Therapeutics' key executives?

Immune Therapeutics' management team includes the following people:
  • Kevin J. Phelps, President, Chief Executive Officer, CFO & Director
  • Rudy J. Williams, Chief Operating Officer
  • Fengping Shan, Chief Science Officer
  • Joseph M. Fortunak, Vice President-Global Research & Development
  • Kathleen A. Browne, Controller

What other stocks do shareholders of Immune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Alexion Pharmaceuticals (ALXN), AK Steel (AKS), Galiano Gold (AKG), Agritek (AGTK), Agenus (AGEN), Affymetrix (AFFX), Advanced Disposal Services (ADSW), Adamis Pharmaceuticals (ADMP) and Analog Devices (ADI).

What is Immune Therapeutics' stock symbol?

Immune Therapeutics trades on the OTCMKTS under the ticker symbol "IMUN."

How do I buy shares of Immune Therapeutics?

Shares of IMUN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immune Therapeutics' stock price today?

One share of IMUN stock can currently be purchased for approximately $1.74.

How much money does Immune Therapeutics make?

Immune Therapeutics has a market capitalization of $838.68 thousand. The company earns $1.59 million in net income (profit) each year or ($61.94) on an earnings per share basis.

How many employees does Immune Therapeutics have?

Immune Therapeutics employs 2 workers across the globe.

What is Immune Therapeutics' official website?

The official website for Immune Therapeutics is www.immunetherapeutics.com.

Where are Immune Therapeutics' headquarters?

Immune Therapeutics is headquartered at 37 NORTH ORANGE AVENUE SUITE 800M, WINTER PARK FL, 32792.

How can I contact Immune Therapeutics?

Immune Therapeutics' mailing address is 37 NORTH ORANGE AVENUE SUITE 800M, WINTER PARK FL, 32792. The company can be reached via phone at (888) 613-8802 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.